Terms: = Lymphoma AND TET2, Q6N021, MGC125715, KIAA1546, FLJ20032, ENSG00000168769, 54790 AND Clinical Outcome
4 results:
1. Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell lymphoma.
Zhu Y; Fu D; Shi Q; Shi Z; Dong L; Yi H; Liu Z; Feng Y; Liu Q; Fang H; Cheng S; Wang L; Tian Q; Xu P; Zhao W
Front Immunol; 2022; 13():842439. PubMed ID: 35401516
[TBL] [Abstract] [Full Text] [Related]
2. Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived lymphoma Phenotypes and outcomes.
Rivas MA; Durmaz C; Kloetgen A; Chin CR; Chen Z; Bhinder B; Koren A; Viny AD; Scharer CD; Boss JM; Elemento O; Mason CE; Melnick AM
Front Immunol; 2021; 12():688493. PubMed ID: 34621263
[TBL] [Abstract] [Full Text] [Related]
3. Low expression of tet2 gene in pediatric acute lymphoblastic leukemia is associated with poor clinical outcome.
Zhang P; Weng WW; Chen P; Zhang Y; Ruan JF; Ba DD; Xu WQ; Tang YM
Int J Lab Hematol; 2019 Oct; 41(5):702-709. PubMed ID: 31441600
[TBL] [Abstract] [Full Text] [Related]
4. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.
Tefferi A
Leuk Lymphoma; 2010 Apr; 51(4):576-82. PubMed ID: 20214447
[TBL] [Abstract] [Full Text] [Related]
